Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 44 entries
Sorted by: Best Match Show Resources per page
Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai.

Bone research

Liu JM, Cusano NE, Silva BC, Zhao L, He XY, Tao B, Sun LH, Zhao HY, Fan WW, Romano ME, Ning G, Bilezikian JP.
PMID: 26273500
Bone Res. 2013 Jun 28;1(2):162-9. doi: 10.4248/BR201302005. eCollection 2013 Jun.

In the 1970s, with the advent of biochemical multichannel screening in the United States and other western countries, the clinical presentation of primary hyperparathyroidism (PHPT) changed from a symptomatic to an asymptomatic disorder. However, in Asian countries, like China,...

Cite
Liu JM, Cusano NE, Silva BC, et al. Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai. Bone Res. 2013;1(2):162-9doi: 10.4248/BR201302005.
Liu, J. M., Cusano, N. E., Silva, B. C., Zhao, L., He, X. Y., Tao, B., Sun, L. H., Zhao, H. Y., Fan, W. W., Romano, M. E., Ning, G., & Bilezikian, J. P. (2013). Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai. Bone research, 1(2), 162-9. https://doi.org/10.4248/BR201302005
Liu, Jian-Min, et al. "Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai." Bone research vol. 1,2 (2013): 162-9. doi: https://doi.org/10.4248/BR201302005
Liu JM, Cusano NE, Silva BC, Zhao L, He XY, Tao B, Sun LH, Zhao HY, Fan WW, Romano ME, Ning G, Bilezikian JP. Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai. Bone Res. 2013 Jun 28;1(2):162-9. doi: 10.4248/BR201302005. eCollection 2013 Jun. PMID: 26273500; PMCID: PMC4472111.
Copy Download .nbib Format: NLM
New Clues that May Link Osteoporosis to the Circulating Lipid Profile.

Bone research

Poiana C, Radoi V, Carsote M, Bilezikian JP.
PMID: 26273507
Bone Res. 2013 Sep 25;1(3):260-6. doi: 10.4248/BR201303004. eCollection 2013 Sep.

Bone Mineral Density (BMD) is a gold standard for the diagnosis of osteoporosis and is also important in the assessment of fracture risk. Other risk factors have been identified that together make up fracture risk assessment tools such as...

Cite
Poiana C, Radoi V, Carsote M, et al. New Clues that May Link Osteoporosis to the Circulating Lipid Profile. Bone Res. 2013;1(3):260-6doi: 10.4248/BR201303004.
Poiana, C., Radoi, V., Carsote, M., & Bilezikian, J. P. (2013). New Clues that May Link Osteoporosis to the Circulating Lipid Profile. Bone research, 1(3), 260-6. https://doi.org/10.4248/BR201303004
Poiana, Catalina, et al. "New Clues that May Link Osteoporosis to the Circulating Lipid Profile." Bone research vol. 1,3 (2013): 260-6. doi: https://doi.org/10.4248/BR201303004
Poiana C, Radoi V, Carsote M, Bilezikian JP. New Clues that May Link Osteoporosis to the Circulating Lipid Profile. Bone Res. 2013 Sep 25;1(3):260-6. doi: 10.4248/BR201303004. eCollection 2013 Sep. PMID: 26273507; PMCID: PMC4472105.
Copy Download .nbib Format: NLM
[No title available]

Pattern recognition letters

Zhou B, Zhang Z, Wang J, Yu YE, Liu XS, Nishiyama KK, Rubin MR, Shane E, Bilezikian JP, Guo XE.
PMID: 27175044
Pattern Recognit Lett. 2016 Jun 01;76:83-89. doi: 10.1016/j.patrec.2015.03.012. Epub 2015 Apr 01.

Trabecular plate and rod microstructure plays a dominant role in the apparent mechanical properties of trabecular bone. With high-resolution computed tomography (CT) images, digital topological analysis (DTA) including skeletonization and topological classification was applied to transform the trabecular three-dimensional...

Cite
Zhou B, Zhang Z, Wang J, et al. . Pattern Recognit Lett. 2015;76:83-89doi: 10.1016/j.patrec.2015.03.012.
Zhou, B., Zhang, Z., Wang, J., Yu, Y. E., Liu, X. S., Nishiyama, K. K., Rubin, M. R., Shane, E., Bilezikian, J. P., & Guo, X. E. (2016). . Pattern recognition letters, 7683-89. https://doi.org/10.1016/j.patrec.2015.03.012
Zhou, Bin, et al. "." Pattern recognition letters vol. 76 (2016): 83-89. doi: https://doi.org/10.1016/j.patrec.2015.03.012
Zhou B, Zhang Z, Wang J, Yu YE, Liu XS, Nishiyama KK, Rubin MR, Shane E, Bilezikian JP, Guo XE. . Pattern Recognit Lett. 2016 Jun 01;76:83-89. doi: 10.1016/j.patrec.2015.03.012. Epub 2015 Apr 01. PMID: 27175044; PMCID: PMC4860735.
Copy Download .nbib Format: NLM
Modulation of host cell metabolism by Trypanosoma cruzi.

Parasitology today (Personal ed.)

Morris SA, Tanowitz HB, Bilezikian JP, Wittner M.
PMID: 15463452
Parasitol Today. 1991 Apr;7(4):82-7. doi: 10.1016/0169-4758(91)90202-y.

Chagas disease, caused by the hemoflagellate Trypanosoma cruzi, is a complicated and devastating disease. It is hypothesized that an important target of infection may be the endothelial cell and that both the acute and chronic forms of the disease...

Cite
Morris SA, Tanowitz HB, Bilezikian JP, et al. Modulation of host cell metabolism by Trypanosoma cruzi. Parasitol Today. 1991;7(4):82-7doi: 10.1016/0169-4758(91)90202-y.
Morris, S. A., Tanowitz, H. B., Bilezikian, J. P., & Wittner, M. (1991). Modulation of host cell metabolism by Trypanosoma cruzi. Parasitology today (Personal ed.), 7(4), 82-7. https://doi.org/10.1016/0169-4758(91)90202-y
Morris, S A, et al. "Modulation of host cell metabolism by Trypanosoma cruzi." Parasitology today (Personal ed.) vol. 7,4 (1991): 82-7. doi: https://doi.org/10.1016/0169-4758(91)90202-y
Morris SA, Tanowitz HB, Bilezikian JP, Wittner M. Modulation of host cell metabolism by Trypanosoma cruzi. Parasitol Today. 1991 Apr;7(4):82-7. doi: 10.1016/0169-4758(91)90202-y. PMID: 15463452.
Copy Download .nbib Format: NLM
Anabolic therapy for osteoporosis.

Women's health (London, England)

Bilezikian JP.
PMID: 19803856
Womens Health (Lond). 2007 Mar;3(2):243-53. doi: 10.2217/17455057.3.2.243.

Antiresorptive agents for osteoporosis are a cornerstone of therapy, but anabolic drugs have recently increased our options. By directly stimulating bone formation, anabolic agents reduce fracture incidence by improving bone qualities as well as increasing bone mass. The anabolic...

Cite
Bilezikian JP. Anabolic therapy for osteoporosis. Womens Health (Lond). 2007;3(2):243-53doi: 10.2217/17455057.3.2.243.
Bilezikian, J. P. (2007). Anabolic therapy for osteoporosis. Women's health (London, England), 3(2), 243-53. https://doi.org/10.2217/17455057.3.2.243
Bilezikian, John P. "Anabolic therapy for osteoporosis." Women's health (London, England) vol. 3,2 (2007): 243-53. doi: https://doi.org/10.2217/17455057.3.2.243
Bilezikian JP. Anabolic therapy for osteoporosis. Womens Health (Lond). 2007 Mar;3(2):243-53. doi: 10.2217/17455057.3.2.243. PMID: 19803856.
Copy Download .nbib Format: NLM
Measurement of parathyroid hormone-related peptide in the circulation.

Trends in endocrinology and metabolism: TEM

Bilezikian JP.
PMID: 18411156
Trends Endocrinol Metab. 1991 Jan-Feb;2(1):1-3. doi: 10.1016/1043-2760(91)90052-o.

Newly developed assays for the measurement of circulating levels of parathyroid hormone-related peptide may become useful in distinguishing the syndrome of humoral hypercalcemia of malignancy from hypercalcemia of other etiologies.

Cite
Bilezikian JP. Measurement of parathyroid hormone-related peptide in the circulation. Trends Endocrinol Metab. 1991;2(1):1-3doi: 10.1016/1043-2760(91)90052-o.
Bilezikian, J. P. (1991). Measurement of parathyroid hormone-related peptide in the circulation. Trends in endocrinology and metabolism: TEM, 2(1), 1-3. https://doi.org/10.1016/1043-2760(91)90052-o
Bilezikian, J P. "Measurement of parathyroid hormone-related peptide in the circulation." Trends in endocrinology and metabolism: TEM vol. 2,1 (1991): 1-3. doi: https://doi.org/10.1016/1043-2760(91)90052-o
Bilezikian JP. Measurement of parathyroid hormone-related peptide in the circulation. Trends Endocrinol Metab. 1991 Jan-Feb;2(1):1-3. doi: 10.1016/1043-2760(91)90052-o. PMID: 18411156.
Copy Download .nbib Format: NLM
Treatment of glucocorticoid-induced osteoporsis.

Therapeutic advances in musculoskeletal disease

Mazziotti G, Giustina A, Canalis E, Bilezikian JP.
PMID: 22870425
Ther Adv Musculoskelet Dis. 2009 Feb;1(1):27-34. doi: 10.1177/1759720X09343222.

Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis. Fractures occur in 30-50% of patients with GIO. Therefore, treatment of this disease is critical. Although patients should receive supplemental calcium and vitamin D, additional measures are necessary...

Cite
Mazziotti G, Giustina A, Canalis E, et al. Treatment of glucocorticoid-induced osteoporsis. Ther Adv Musculoskelet Dis. 2009;1(1):27-34doi: 10.1177/1759720X09343222.
Mazziotti, G., Giustina, A., Canalis, E., & Bilezikian, J. P. (2009). Treatment of glucocorticoid-induced osteoporsis. Therapeutic advances in musculoskeletal disease, 1(1), 27-34. https://doi.org/10.1177/1759720X09343222
Mazziotti, Gherardo, et al. "Treatment of glucocorticoid-induced osteoporsis." Therapeutic advances in musculoskeletal disease vol. 1,1 (2009): 27-34. doi: https://doi.org/10.1177/1759720X09343222
Mazziotti G, Giustina A, Canalis E, Bilezikian JP. Treatment of glucocorticoid-induced osteoporsis. Ther Adv Musculoskelet Dis. 2009 Feb;1(1):27-34. doi: 10.1177/1759720X09343222. PMID: 22870425; PMCID: PMC3382670.
Copy Download .nbib Format: NLM
Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism.

Reviews in endocrine & metabolic disorders

Gosmanova EO, Houillier P, Rejnmark L, Marelli C, Bilezikian JP.
PMID: 33599907
Rev Endocr Metab Disord. 2021 Jun;22(2):297-316. doi: 10.1007/s11154-020-09613-1. Epub 2021 Feb 18.

A systematic literature review was performed to summarize the frequency and nature of renal complications in patients with chronic hypoparathyroidism managed with conventional therapy. Methodology was consistent with the recommendations outlined in the Preferred Reporting Items for Systematic Reviews...

Cite
Gosmanova EO, Houillier P, Rejnmark L, et al. Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism. Rev Endocr Metab Disord. 2021;22(2):297-316doi: 10.1007/s11154-020-09613-1.
Gosmanova, E. O., Houillier, P., Rejnmark, L., Marelli, C., & Bilezikian, J. P. (2021). Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism. Reviews in endocrine & metabolic disorders, 22(2), 297-316. https://doi.org/10.1007/s11154-020-09613-1
Gosmanova, Elvira O, et al. "Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism." Reviews in endocrine & metabolic disorders vol. 22,2 (2021): 297-316. doi: https://doi.org/10.1007/s11154-020-09613-1
Gosmanova EO, Houillier P, Rejnmark L, Marelli C, Bilezikian JP. Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism. Rev Endocr Metab Disord. 2021 Jun;22(2):297-316. doi: 10.1007/s11154-020-09613-1. Epub 2021 Feb 18. PMID: 33599907; PMCID: PMC8087595.
Copy Download .nbib Format: NLM
Vitamin D status in Armenian women: a stratified cross-sectional cluster analysis.

European journal of clinical nutrition

Hutchings N, Babalyan V, Heijboer AC, Baghdasaryan S, Qefoyan M, Ivanyan A, Ackermans MT, Formenti AM, Lesnyak O, Giustina A, Bilezikian JP.
PMID: 33986494
Eur J Clin Nutr. 2021 May 13; doi: 10.1038/s41430-021-00934-1. Epub 2021 May 13.

BACKGROUND: Vitamin D plays a critical role in skeletal development and maintenance, thus sufficiency is an important goal for public health programs. Given the absence of foods fortified in vitamin D in Armenia, we hypothesized that vitamin D insufficiency...

Cite
Hutchings N, Babalyan V, Heijboer AC, et al. Vitamin D status in Armenian women: a stratified cross-sectional cluster analysis. Eur J Clin Nutr. 2021;doi: 10.1038/s41430-021-00934-1.
Hutchings, N., Babalyan, V., Heijboer, A. C., Baghdasaryan, S., Qefoyan, M., Ivanyan, A., Ackermans, M. T., Formenti, A. M., Lesnyak, O., Giustina, A., & Bilezikian, J. P. (2021). Vitamin D status in Armenian women: a stratified cross-sectional cluster analysis. European journal of clinical nutrition, . https://doi.org/10.1038/s41430-021-00934-1
Hutchings, Nicholas, et al. "Vitamin D status in Armenian women: a stratified cross-sectional cluster analysis." European journal of clinical nutrition vol. (2021). doi: https://doi.org/10.1038/s41430-021-00934-1
Hutchings N, Babalyan V, Heijboer AC, Baghdasaryan S, Qefoyan M, Ivanyan A, Ackermans MT, Formenti AM, Lesnyak O, Giustina A, Bilezikian JP. Vitamin D status in Armenian women: a stratified cross-sectional cluster analysis. Eur J Clin Nutr. 2021 May 13; doi: 10.1038/s41430-021-00934-1. Epub 2021 May 13. PMID: 33986494.
Copy Download .nbib Format: NLM
PTH(1-84) replacement therapy for the treatment of hypoparathyroidism.

Expert review of endocrinology & metabolism

Cusano NE, Rubin MR, Bilezikian JP.
PMID: 25705243
Expert Rev Endocrinol Metab. 2015 Jan 01;10(1):5-13. doi: 10.1586/17446651.2015.971755.

Hypoparathyroidism is a rare disease characterized by hypocalcemia and insufficient circulating levels of parathyroid hormone (PTH). Conventional therapy includes calcium and active vitamin D supplementation, often in large doses. Therapy with calcium and vitamin D, however, does not address...

Cite
Cusano NE, Rubin MR, Bilezikian JP. PTH(1-84) replacement therapy for the treatment of hypoparathyroidism. Expert Rev Endocrinol Metab. 2015;10(1):5-13doi: 10.1586/17446651.2015.971755.
Cusano, N. E., Rubin, M. R., & Bilezikian, J. P. (2015). PTH(1-84) replacement therapy for the treatment of hypoparathyroidism. Expert review of endocrinology & metabolism, 10(1), 5-13. https://doi.org/10.1586/17446651.2015.971755
Cusano, Natalie E, et al. "PTH(1-84) replacement therapy for the treatment of hypoparathyroidism." Expert review of endocrinology & metabolism vol. 10,1 (2015): 5-13. doi: https://doi.org/10.1586/17446651.2015.971755
Cusano NE, Rubin MR, Bilezikian JP. PTH(1-84) replacement therapy for the treatment of hypoparathyroidism. Expert Rev Endocrinol Metab. 2015 Jan 01;10(1):5-13. doi: 10.1586/17446651.2015.971755. PMID: 25705243; PMCID: PMC4334142.
Copy Download .nbib Format: NLM
Primary Hyperparathyroidism.

F1000Research

Bandeira L, Bilezikian J.
PMID: 27508075
F1000Res. 2016 Jan 04;5. doi: 10.12688/f1000research.7039.1. eCollection 2016.

Over the past several generations, primary hyperparathyroidism (PHTP) has undergone a change in its clinical presentation in many countries from a symptomatic disease to an asymptomatic one. The reasons for this change in clinical presentation are related to the...

Cite
Bandeira L, Bilezikian J. Primary Hyperparathyroidism. F1000Res. 2016;5doi: 10.12688/f1000research.7039.1.
Bandeira, L., & Bilezikian, J. (2016). Primary Hyperparathyroidism. F1000Research, 5. https://doi.org/10.12688/f1000research.7039.1
Bandeira, Leonardo, and Bilezikian, John. "Primary Hyperparathyroidism." F1000Research vol. 5 (2016). doi: https://doi.org/10.12688/f1000research.7039.1
Bandeira L, Bilezikian J. Primary Hyperparathyroidism. F1000Res. 2016 Jan 04;5. doi: 10.12688/f1000research.7039.1. eCollection 2016. PMID: 27508075; PMCID: PMC4963029.
Copy Download .nbib Format: NLM
Erratum to: Taxonomy of rare genetic metabolic bone disorders.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Masi L, Agnusdei D, Bilezikian J, Chappard D, Chapurlat R, Cianferotti L, Devolgelaer JP, El Maghraoui A, Ferrari S, Javaid K, Kaufman JM, Liberman UA, Lyritis G, Miller P, Napoli N, Roldan E, Papapoulos S, Watts NB, Brandi ML.
PMID: 26370825
Osteoporos Int. 2015 Nov;26(11):2717-8. doi: 10.1007/s00198-015-3237-4.

No abstract available.

Cite
Masi L, Agnusdei D, Bilezikian J, et al. Erratum to: Taxonomy of rare genetic metabolic bone disorders. Osteoporos Int. 2015;26(11):2717-8doi: 10.1007/s00198-015-3237-4.
Masi, L., Agnusdei, D., Bilezikian, J., Chappard, D., Chapurlat, R., Cianferotti, L., Devolgelaer, J. P., El Maghraoui, A., Ferrari, S., Javaid, K., Kaufman, J. M., Liberman, U. A., Lyritis, G., Miller, P., Napoli, N., Roldan, E., Papapoulos, S., Watts, N. B., & Brandi, M. L. (2015). Erratum to: Taxonomy of rare genetic metabolic bone disorders. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 26(11), 2717-8. https://doi.org/10.1007/s00198-015-3237-4
Masi, L, et al. "Erratum to: Taxonomy of rare genetic metabolic bone disorders." Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA vol. 26,11 (2015): 2717-8. doi: https://doi.org/10.1007/s00198-015-3237-4
Masi L, Agnusdei D, Bilezikian J, Chappard D, Chapurlat R, Cianferotti L, Devolgelaer JP, El Maghraoui A, Ferrari S, Javaid K, Kaufman JM, Liberman UA, Lyritis G, Miller P, Napoli N, Roldan E, Papapoulos S, Watts NB, Brandi ML. Erratum to: Taxonomy of rare genetic metabolic bone disorders. Osteoporos Int. 2015 Nov;26(11):2717-8. doi: 10.1007/s00198-015-3237-4. PMID: 26370825.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 44 entries